Alivus Life Sciences Limited (NSE:ALIVUS)

India flag India · Delayed Price · Currency is INR
1,001.30
+6.70 (0.67%)
At close: Jun 27, 2025, 3:30 PM IST
-0.46%
Market Cap 122.79B
Revenue (ttm) 23.87B
Net Income (ttm) 4.86B
Shares Out 122.63M
EPS (ttm) 39.52
PE Ratio 25.34
Forward PE 22.55
Dividend 5.00 (0.50%)
Ex-Dividend Date n/a
Volume 69,747
Average Volume 94,004
Open 1,010.00
Previous Close 994.60
Day's Range 992.00 - 1,010.00
52-Week Range 850.00 - 1,251.00
Beta 0.16
RSI 41.63
Earnings Date Jul 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in... [Read more]

Sector Healthcare
Founded 2011
Employees 2,014
Stock Exchange National Stock Exchange of India
Ticker Symbol ALIVUS
Full Company Profile

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.

Financial Statements

News

There is no news available yet.